RedHill Biopharma (RDHL) EBIT (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of EBIT data on file, last reported at $53.8 million in Q2 2023.

• On a quarterly basis, EBIT rose 486.88% year-over-year to $53.8 million in Q2 2023; TTM through Jun 2023 was -$44.0 million, a 55.32% increase from a year earlier, with the FY2025 full-year figure at -$7.9 million, down 22.66% from the prior year.
• EBIT for Q2 2023 stood at $53.8 million, up from -$29.1 million in the prior quarter.
• Over the last five years, EBIT for RDHL reached as high as $53.8 million in Q2 2023 and fell as low as -$141.6 million in Q4 2021.
• Historically, EBIT has averaged $421000.0 across 5 years, with a median of $12.4 million in 2019.
• Across the five-year window, EBIT slumped 818.34% in 2021 and surged 486.88% in 2023, its largest moves.
• Year by year, EBIT stood at $11.8 million in 2019, then surged by 67.53% to $19.7 million in 2020, then slumped by 818.34% to -$141.6 million in 2021, then soared by 46.5% to -$75.7 million in 2022, then surged by 170.97% to $53.8 million in 2023.
• Per Business Quant data, the three most recent EBIT figures were $53.8 million in Q2 2023, -$29.1 million in Q1 2023, and -$75.7 million in Q4 2022.